Sunday, November 19, 2017

CDXC…Tru Niagen is Off to the Races

ChromaDex (CDXC) reported earnings yesterday. As expected, they lost money during this period where they are investing in the development of Tru Niagen as...

ChromaDex Reports Third Quarter 2017 Financial Results

IRVINE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today the financial results for...

CDXC: Could Tru Niagen Start Trending???

Yesterday Chromadex announced the pricing of a private placement for $23M dollars. This deal was significant to the Company in that they have padded...

ChromaDex Announces $23 million Private Placement of Common Stock

Tailwinds' Take: This financing was led by ICONIQ Capital, which is a Mark Zuckerberg led investment fund. All other investors (except one small one...

ChromaDex Appoints Kevin Farr as New CFO

Tailwinds' Take: a great new hire for the Company, Farr has the experience to help build Tru Niagen into a global consumer brand. His...

ChromaDex Announces Top-line Results of its Second Human Clinical Trial

Tailwinds' Take: very positive news for CDXC as this demonstrates the positive effects of Niagen in anti-aging activity. Expect more studies to continue showing...

ChromaDex and The IP Around NR

As an investor in ChromaDex (CDXC), and a user of their lead product Tru Niagen, I'm a firm believer in the health benefits of...

ChromaDex Partners with Asia’s Leading Health and Beauty Retailer, Watsons, for TRU NIAGEN™ Retail...

Tailwinds' Take: Watsons is a great partner. The Asian market is the largest for sales of supplements and Tru Niagen is poised to be...

ChromaDex Announces Closing of Third and Final Tranche

Tailwinds' Take: this completes the strategic financing. Li Ka-shing owns a chain of pharmacies and has incredible reach into Asia, including China. As such,...

ChromaDex Reports Second Quarter 2017 Financial Results

Company Reports Revenue of $5.3 Million for Q2 2017-  Continued Progress on Building a Consumer Products Platform Around TruNiagen®- IRVINE, Calif., Aug. 10, 2017...

ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific...

IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food...

Adding Chromadex (CDXC) to the Tailwinds Select Portfolio

This morning we have added Chromadex to the Tailwinds Select Portfolio at a price of $3.91. Chromadex holds the worldwide rights to Niagen, a...

ChromaDex Announces Agreement with The Scripps Research Institute

IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food...

ChromaDex Names World’s Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor

IRVINE, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address